 |
|
Polyneuropathies Associated With IgM Monoclonal Gammopathies
John J. Kelly, MD;
Lester S. Adelman, MD;
Eugene Berkman, MD;
Ina Bhan, MD
Arch Neurol. 1988;45(12):1355-1359.
Abstract
• We studied ten patients with IgM monoclonal gammopathies. Five had M proteins that reacted with myelin-associated glycoprotein (MAG) and five had no recognizable antinerve activity. The neuropathy in the MAG-reactive patients was homogeneous by clinical and laboratory analysis, while the neuropathy in the MAG-nonreactive patients varied considerably. Both groups responded well to immunosuppressive therapy, which lowered the concentration of the serum M protein. The homogeneity of the MAG-reactive patients and their response to sustained lowering of the M protein levels support the concept that the IgM M protein directly damages nerve fibers and is the proximate cause of the polyneuropathy.
Author Affiliations
From the Departments of Neurology (Dr Kelly), Pathology (Drs Adelman and Bhan), and Internal Medicine (Dr Berkman), Tufts Medical School and New England Medical Center, Boston.
Footnotes
Accepted for publication June 20, 1988.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cladribine in the treatment of IgM paraproteinemic polyneuropathy
Ghosh et al.
Neurology 2002;59:1290-1291.
FULL TEXT
Neuropathy and IgM M-proteins: Prognostic value of antibodies to MAG, SGPG, and sulfatide
Eurelings et al.
Neurology 2001;56:228-233.
ABSTRACT
| FULL TEXT
Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies
Nobile-Orazio et al.
Brain 2000;123:710-717.
ABSTRACT
| FULL TEXT
Distal acquired demyelinating symmetric neuropathy
Katz et al.
Neurology 2000;54:615-615.
ABSTRACT
| FULL TEXT
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine
Wilson et al.
J. Neurol. Neurosurg. Psychiatry 1999;66:575-580.
ABSTRACT
| FULL TEXT
|
